Cargando…
SHOULD BETA BLOCKERS STILL BE CONSIDERED SECOND LINE IN PATIENTS WITH SARS-COV-2
Autores principales: | Tan, Samuel, Douen, Aaron, Sukhoo-Pertab, Marc L., Siu, Wenchy, Mondal, Avilash, Toreli, Aleksandre |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American College of Cardiology Foundation. Published by Elsevier Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9983040/ http://dx.doi.org/10.1016/S0735-1097(23)02235-0 |
Ejemplares similares
-
ASSOCIATION BETWEEN CARDIOVASCULAR COMORBIDITIES AND MORTALITY AMONGST SARSCOV-2 PATIENTS
por: Douen, Aaron, et al.
Publicado: (2022) -
BODY MASS INDEX, INFLAMMATION AND SEVERITY IN HOSPITALIZED COVID-19 PATIENTS: RESULTS FROM A CHICAGO AND MADRID RETROSPECTIVE COHORT STUDY
por: Park, Aaron, et al.
Publicado: (2023) -
THE ASSOCIATION OF ANTICOAGULATION BEFORE ADMISSION AND SURVIVAL OF PATIENTS WITH COVID-19
por: Kuno, Toshiki, et al.
Publicado: (2021) -
SOCIAL DETERMINANTS OF HEALTH DISPARITIES FOR COVID-19 MITIGATION MEASURES AMONG ADULTS WITH CARDIOVASCULAR DISEASE IN UNITED STATES
por: Hagan, Kobina, et al.
Publicado: (2021) -
IMPACT OF CARDIOVASCULAR RISK FACTOR CONTROL AND HEALTH CARE RESOURCE UTILIZATION DURING THE COVID-19 PANDEMIC
por: Cho, Kenneth Kunhee, et al.
Publicado: (2022)